ライフサイエンスコーパス: hematologic disease

1 improved therapies for benign and malignant hematologic disease.

2 in patients with malignant and non-malignant hematologic disease.

3 -4.3) for trauma to 8.7 (95% CI, 6.8-11) for hematologic disease.

4 provide insights into inherited and acquired hematologic disease.

5 l transplantation, in patients with advanced hematologic disease.

6 te hematopoiesis but may also be relevant to hematologic disease.

7 geted therapy as a new treatment modality in hematologic disease.

8 en given to its effect on the development of hematologic disease.

9 d diagnosis and treatment for this important hematologic disease.

10 f choice for treatment of intractable benign hematologic disease.

11 ne of the affected patients had a history of hematologic disease.

12 n the microbiota's role in hematopoiesis and hematologic diseases.

13 antation, a potentially curative therapy for hematologic diseases.

14 berrant PKA signaling in the pathogenesis of hematologic diseases.

15 ved as a curative modality for patients with hematologic diseases.

16 thought to contribute to the development of hematologic diseases.

17 at promise for cell-based therapies to treat hematologic diseases.

18 investigation and for clinical diagnosis of hematologic diseases.

19 is a curative procedure for life-threatening hematologic diseases.

20 cyte (MN) recruitment in immune-mediated and hematologic diseases.

21 s too low for effective gene therapy of most hematologic diseases.

22 deal treatment strategy for many genetic and hematologic diseases.

23 he treatment of a large number of congenital hematologic diseases.

24 th laparoscopic splenectomy in patients with hematologic diseases.

25 ng nonmalignant non-primary immunodeficiency hematologic disease (15.4%; p = 0.020), metabolic disord

26 rge and were alive and in remission of their hematologic disease after a follow-up of 18 (range, 5-30

27 of patients with several types of malignant hematologic disease and hematologic disorders; however,

28 und in PB lymphocytes of patients with other hematologic diseases and heavy transfusion burdens or in

29 aving therapy for malignant and nonmalignant hematologic diseases and metabolic disorders.

30 nd therapy of cardiovascular, pulmonary, and hematologic diseases and sleep disorders.

31 ans for studying the role of phytosterols in hematologic diseases and testing therapeutic interventio

32 mal HSC biology, featuring aspects of aging, hematologic disease, and how this circuitry may be explo

33 mycosis fungoides, inflammatory cutaneous or hematologic diseases, and from healthy volunteers.

34 comparable to those of open splenectomy for hematologic diseases, and it appears to retain other pat

35 e a treatment for patients with nonmalignant hematologic diseases, and may tolerize patients to organ

36 type I, which is seen exclusively in clonal hematologic diseases, and type II/III, which is called m

37 Several rare hematologic diseases are associated with acquired or inh

38 nd, but diagnostic criteria for MDS or other hematologic diseases are not fulfilled, a condition term

39 the prophylactic transfusion of platelets in hematologic diseases are well described, relatively litt

40 ia is a critical problem that occurs in many hematologic diseases, as well as after cancer therapy an

41 uired severe aplastic anemia (SAA) is a rare hematologic disease associated with significant morbidit

42 es, including cancer (B-H P = 3.75E(-9)) and hematologic disease (B-H P = 8.01E(-8)).

43 vectors may be effective in the treatment of hematologic diseases by gene therapy.

44 Pure red-cell aplasia (PRCA) is a rare hematologic disease characterized by anemia, reticulocyt

45 Polycythemia vera (PV) is a clonal hematologic disease characterized by hyperplasia of the

46 juvenile myelomonocytic leukemia, are clonal hematologic diseases characterized by myeloid dysplasia,

47 omes (MDSs) are collections of heterogeneous hematologic diseases characterized by refractory cytopen

48 estigation of how biophysical alterations in hematologic disease collectively lead to microvascular o

49 tients referred for elective splenectomy for hematologic disease from March 1992 to March 1995.

50 otein (EGFP) controls, which did not develop hematologic disease (> 200 days).

51 lobinuria (PNH), a rare but life-threatening hematologic disease, has fundamentally improved with the

52 e for cladribine (2CdA) therapy of malignant hematologic diseases have not been determined.

53 Medications for hematologic diseases have the potential to modulate thes

54 shown to be involved in the pathogenesis of hematologic disease in animal models.

55 ividually play a role in the pathogenesis of hematologic disease in mice.

56 alized patient dying with advanced cancer or hematologic disease in which the limitation of life-sust

57 ow as well as for study of hematopoiesis and hematologic diseases in vitro.

58 Thirteen patients showed evolution to other hematologic diseases, including monosomy 7.

59 entiation, and iron overload in a variety of hematologic diseases is associated with excessive bone r

60 Aplastic anemia, an unusual hematologic disease, is the paradigm of the human bone m

61 inactive granulomata, or even the underlying hematologic disease itself (especially in patients with

62 native for patients with high-risk malignant hematologic diseases, lacking an HLA identical sibling a

63 take-associated alterations in patients with hematologic disease on triazol antifungal medication.

64 eukemia (AML) varies as a result of previous hematologic disease or can be explained by differences i

65 have been implicated in the pathogenesis of hematologic diseases other than chronic myelogenous leuk

66 ause of the association of mastocytosis with hematologic disease, plasma levels were measured for sol

67 to analyze the impact of CMV reactivation on hematologic disease relapse in the current era.

68 CMV reactivation had no preventive effect on hematologic disease relapse irrespective of diagnosis.

69 d does not seem to confer protection against hematologic disease relapse.

70 t relapse and especially evolution of clonal hematologic diseases remain problematic.

71 arameters out of normal range as a result of hematologic disease should be included in trials.

72 astic anemia (AA) is its evolution to clonal hematologic diseases such as myelodysplasia (MDS) and le

73 bers has been associated with multiple human hematologic diseases such as neutrophil dysfunction, leu

74 uring an immune response and in premalignant hematologic diseases, such as MDS.

75 In hematologic diseases, such as sickle cell disease (SCD)

76 ute promyelocytic leukemia is one of the few hematologic diseases that must be recognized under the m

77 n factors V and VIII (F5F8D) are the 2 known hematologic diseases that result from defects in the end

78 antation mortality is greater than for other hematologic diseases, treatment leads to durable hematol

79 One hundred ten patients with hematologic disease were enrolled.

80 transfused patients with non-immune-mediated hematologic diseases were used as controls.

81 topoietic stem cell source for patients with hematologic diseases who can be cured by allogeneic hema

82 e only curative treatment for many malignant hematologic diseases, with an often critical graft-versu